PsiOxus Therapeutics is now Akamis Bio! Along with this name change, today we announced a $30 million convertible note financing led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, & Westlake Village BioPartners® that will further leverage our T-SIGn® tumor gene therapy platform. CEO Howard E. Davis, Ph.D., and our team remain unwearying in our dedication to creating groundbreaking treatments for people fighting #cancer and work towards paving the way to a better future for #cancer care. https://bwnews.pr/3WOSqcC #innovation #oncology #solidtumors
Akamis Bio
Biotechnology Research
Abingdon, Oxfordshire 7,302 followers
Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer
About us
Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI) To learn more, please visit www.akamisbio.com.
- Website
-
www.akamisbio.com
External link for Akamis Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Abingdon, Oxfordshire
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Immuno-oncology and Re-programming the Tumor Microenvironment
Locations
-
Primary
Get directions
4-10 The Quadrant, Barton Lane
Abingdon, Oxfordshire OX14 3YS, GB
-
Get directions
245 Main Street
2nd Floor
Cambridge, MA 02142, US
Employees at Akamis Bio
Updates
-
Our Senior Vice President and Head of Research, Samantha Bailey-Bucktrout joins Tom Froggatt on the Careers in Discovery podcast to discuss key learnings from her career and current role at Akamis Bio – and the evolution of the Company’s Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform for the treatment of solid tumors. Tune in to hear more: https://bit.ly/3uzQlYV #innovation #cancer
-
-
Akamis Bio reposted this
"I see all the other element of my current role - the leadership, management and mentoring - as enabling the science." Samantha Bailey-Bucktrout is the Senior Vice President of Research at Akamis Bio, a company harnessing the power of tumour gene therapy in the fight against cancer. Samantha talked to us about her career in cancer immunotherapy, what Greek mythology has to do with modern-day Biotech, and the importance of a collaborative approach to drug development. To listen to the interview, search "Careers in Discovery" on Spotify, iTunes, Apple Podcasts or Google Podcasts, or follow the link in the comments. Enjoy! Jason Glashow #podcast #leadership #biotechnology #biotech #drugdiscovery #drugdevelopment #genetherapy #oncology #cancer #cancerresearch
-
-
Samantha Bailey-Bucktrout will be speaking at the #PEGSEurope Conference to discuss how we use our T-SIGn adenovirus platform for tumor-selective expression of novel antibody formats and combinations, immunomodulatory proteins that combine with CAR-T to clear resistant solid tumors and recent advances in our lead clinical program NG-350A https://bit.ly/3Szx1F8 #ImmunoOncology #CancerResearch
-
-
Akamis Bio reposted this
Delighted to announce an exceptionally strong female speaker line-up for this years #PEGS Europe Conference on our Emerging #Targets and #Therapeutic Approaches Conference. Please join us in lovely Lisbon, this November, where we explore unconventional approaches for clinical success in #oncology and beyond. Kerry Chester, UCL will chair this conference stream including presentations from Samantha Bailey-Bucktrout, Akamis Bio, Xiaole Shirley Liu GV20 Therapeutics, Annelise Vuidepot, PhD, Immunocore, and Sandra E., University of Cambridge https://lnkd.in/enE2RgxZ #PEGSEurope #oncology #biopharma #biologics #proteinengineering #proteinexpression #immunotherapy
-
Akamis Bio CEO Howard E. Davis, Ph.D., spoke with Daniel Levine on The Bio Report podcast where they discussed the challenges faced by #immunotherapies in treating #solidtumors, and the potential of Akamis Bio’s T-SIGn therapeutics to deliver and express transgenes that can create an anti-tumor immune response at both primary and metastatic tumor sites. Listen now: https://bit.ly/3M55NSO
-
-
Today, Akamis Bio will share data from the Phase 1 CEDAR #study which showed improved responses in patients with locally advanced rectal #cancer treated with our adenovirus vector #technology in combination with radiotherapy, over radiation alone. The study data will be presented today at the 2023 American Society for Radiation Oncology Annual Meeting in San Diego. Learn more: https://bit.ly/46dRRxX #ASTRO2023
-
-
Learn more about Akamis Bio’s lead program, NG-350A, a Phase 1 immuno-stimulatory #genetherapy that aims to safely drive intra-tumoral expression of a potent CD-40 agonist to treat solid #cancer tumors: https://bit.ly/3pPRxoR
Our Pipeline | Akamis Bio | Tumor Gene Therapy
akamisbio.com
-
Akamis Bio is working to broaden the potential of immunotherapy for solid tumors, addressing the safety and efficacy challenges with I.V. administered, tumor-specific therapeutics that can generate a potent immune response and avoid systemic toxicity. Learn about our T-SIGn® tumor gene therapy platform here: https://bit.ly/3pPRxoR #ImmunoOncology #CancerResearch #Oncology
-
-
Check out this recent article from Cell & Gene featuring our CEO, Howard E. Davis, Ph.D., discussing Akamis Bio’s portfolio of solid tumor-targeted T-SIGn #therapeutics, our NG-350A clinical trial, and how T-SIGn is broadening the impact of cell therapy in #solidtumors: https://bit.ly/45QO3T2
-